Description
CJC-1295 No DAC + Ipamorelin — Growth Hormone Signalling Research Blend
CJC-1295 No DAC + Ipamorelin is a two-component research formulation containing 5 mg of CJC-1295 No DAC and 5 mg of ipamorelin, for a stated combined peptide quantity of 10 mg.
CJC-1295 No DAC is commonly used as a commercial name for modified growth hormone-releasing factor (Mod GRF 1-29), while ipamorelin is a synthetic growth hormone secretagogue peptide.
These compounds are investigated for their interactions with different receptor pathways involved in growth hormone regulation. Research on either compound individually does not establish the biological activity, safety, or effectiveness of the combined formulation.
Research Highlights
Dual-component formulation: CJC-1295 No DAC and ipamorelin combined in one research product.
GHRH receptor research: Investigation into modified growth hormone-releasing factor and pituitary signalling.
Secretagogue receptor activity: Research examining ipamorelin and its interactions with growth hormone secretagogue receptors.
Endocrine signalling: Studies involving hormonal pathways associated with growth hormone regulation.
Peptide structure: Investigation into molecular differences between DAC and non-DAC growth hormone-releasing peptides.
Combination research: Questions concerning potential interactions between two distinct receptor signalling pathways.
Evidence limitations: Human safety, therapeutic effectiveness, and claimed synergy have not been established for this specific blend.
These highlights describe scientific research topics associated with the ingredients. They do not establish benefits or validate the quality of an individual research product.
Understanding the Two Components
CJC-1295 No DAC — 5 mg
CJC-1295 No DAC commonly refers to modified growth hormone-releasing factor (Mod GRF 1-29), a synthetic peptide derived from the active region of growth hormone-releasing hormone.
It is investigated for its ability to interact with GHRH receptors involved in regulating pituitary growth hormone secretion.
The No DAC designation indicates the absence of the drug affinity complex modification associated with longer-acting CJC-1295 formulations.
Research findings involving DAC-modified CJC-1295 should not automatically be attributed to the non-DAC molecule.
Ipamorelin — 5 mg
Ipamorelin is a synthetic pentapeptide investigated for its activity at growth hormone secretagogue receptors.
Scientific studies have examined its interactions with growth hormone release pathways, including experimental investigations into receptor activity and endocrine responses.
Ipamorelin acts through a receptor system distinct from the GHRH pathway associated with modified GRF(1-29).
These mechanistic differences provide a basis for comparing separate aspects of growth hormone regulation.
Growth Hormone & Pituitary Signalling Research
Growth hormone secretion is regulated through interacting hypothalamic, pituitary, and peripheral signalling pathways.
GHRH receptor activity contributes to growth hormone release, while growth hormone secretagogue receptors represent a separate regulatory mechanism.
The two ingredients in this blend are associated with these different signalling systems.
Researchers may investigate how receptor pathways interact in experimental models. However, combining the ingredients does not establish that their effects are additive, synergistic, or clinically beneficial.
CJC-1295 No DAC vs. CJC-1295 With DAC
The distinction between DAC and non-DAC formulations is important when interpreting scientific findings.
CJC-1295 with DAC incorporates a drug affinity complex designed to influence the peptide’s interaction with circulating albumin and its duration of activity.
CJC-1295 No DAC lacks this modification and is commonly identified with modified GRF(1-29).
The two forms should be treated as distinct research materials. Their molecular identity should be confirmed through sequence and analytical documentation rather than product naming alone.
What Makes This Blend Scientifically Distinct?
The defining feature of the formulation is the combination of two peptides associated with different growth hormone regulatory pathways.
CJC-1295 No DAC is investigated through GHRH receptor-related signalling, while ipamorelin is associated with growth hormone secretagogue receptor activity.
These distinct mechanisms create questions about receptor interactions and hormonal responses in experimental research.
The presence of both compounds does not establish superior outcomes or reproduce the findings of studies involving either ingredient alone.
Considerations for Laboratory Researchers
When selecting research material, researchers should consider:
Documentation confirming the precise identity of the non-DAC peptide.
Verification of the stated amount of each component.
Whether analytical testing distinguishes the two peptides.
Confirmation that testing corresponds to the supplied batch.
Formulation compatibility, stability, and storage requirements.
Suitability for the intended laboratory protocol.
A purity percentage alone does not establish sterility, absence of endotoxins, or suitability for administration. Evidence involving individual peptides does not independently establish the quality of the combined formulation.
Storage & Handling
Unopened research material
Follow the storage temperature specified on the product label and supporting batch documentation.
Protect from light and moisture.
Keep the container tightly sealed until needed.
Avoid repeated temperature swings and freeze–thaw cycles.
Storage and stability requirements should be supported by information specific to the combined formulation. Conditions and usable periods after reconstitution require separate guidance.
Frequently Asked Questions
What is CJC-1295 No DAC + Ipamorelin?
It is a two-component research formulation containing a modified growth hormone-releasing factor peptide and ipamorelin.
What does No DAC mean?
No DAC indicates the absence of the drug affinity complex modification associated with certain CJC-1295 formulations.
Is CJC-1295 No DAC the same as CJC-1295 with DAC?
No. They are chemically distinct research materials, and findings involving one form should not automatically be attributed to the other.
What is ipamorelin?
Ipamorelin is a synthetic growth hormone secretagogue peptide investigated for its receptor activity and effects on growth hormone-related signalling.
Has the combination been proven more effective than either ingredient individually?
No established clinical evidence demonstrates superior therapeutic effectiveness or synergy for this specific formulation. Such claims require direct comparative research.
What does 5 mg / 5 mg mean?
It refers to the stated quantity of each peptide: 5 mg of CJC-1295 No DAC and 5 mg of ipamorelin. The combined quantity is 10 mg. These values are not recommended doses or administration instructions.
Is this product intended for personal use?
No. This product is designated for laboratory research only and is not intended for human or veterinary administration.
Laboratory Research Only
Not for human or animal administration. Information on this page describes scientific research and does not provide medical advice, dosing instructions, or treatment recommendations. Research findings are not guarantees of experimental results.
